Literature DB >> 31813089

Current progress and future direction in the treatment for hemophilia.

Midori Shima1.   

Abstract

Entities:  

Year:  2019        PMID： 31813089     DOI： 10.1007/s12185-019-02786-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  24 in total

1.  A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.

Authors:  H Eichler; P Angchaisuksiri; K Kavakli; P Knoebl; J Windyga; V Jiménez-Yuste; A Hyseni; U Friedrich; P Chowdary
Journal:  J Thromb Haemost       Date:  2018-09-30       Impact factor: 5.824

2.  Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086.

Authors:  Chuenlei Parng; Pratap Singh; Debra D Pittman; Katherine Wright; Beth Leary; Sunita Patel-Hett; Swapnil Rakhe; James Stejskal; Marjorie Peraza; Dawn Dufield; John E Murphy; Rob Webster
Journal:  J Pharm Sci       Date:  2018-03-20       Impact factor: 3.534

3.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Authors:  Johnny Mahlangu; Johannes Oldenburg; Ido Paz-Priel; Claude Negrier; Markus Niggli; M Elisa Mancuso; Christophe Schmitt; Victor Jiménez-Yuste; Christine Kempton; Christophe Dhalluin; Michael U Callaghan; Willem Bujan; Midori Shima; Joanne I Adamkewicz; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

4.  Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.

Authors:  Emily K Waters; Ryan M Genga; Michael C Schwartz; Jennifer A Nelson; Robert G Schaub; Karen A Olson; Jeffrey C Kurz; Kathleen E McGinness
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

5.  Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.

Authors:  Jian-Ming Gu; Xiao-Yan Zhao; Thomas Schwarz; Joachim Schuhmacher; Andreas Baumann; Elena Ho; Babu Subramanyan; Kathy Tran; Timothy Myles; Chandra Patel; Maria Koellnberger
Journal:  AAPS J       Date:  2017-05-17       Impact factor: 4.009

Review 6.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

7.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

Authors:  Midori Shima; Hideji Hanabusa; Masashi Taki; Tadashi Matsushita; Tetsuji Sato; Katsuyuki Fukutake; Naoki Fukazawa; Koichiro Yoneyama; Hiroki Yoshida; Keiji Nogami
Journal:  N Engl J Med       Date:  2016-05-26       Impact factor: 91.245

Review 8.  Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.

Authors:  Pratima Chowdary
Journal:  Int J Hematol       Date:  2018-10-09       Impact factor: 2.490

9.  Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.

Authors:  P Chowdary; S Lethagen; U Friedrich; B Brand; C Hay; F Abdul Karim; R Klamroth; P Knoebl; M Laffan; J Mahlangu; W Miesbach; J Dalsgaard Nielsen; M Martín-Salces; P Angchaisuksiri
Journal:  J Thromb Haemost       Date:  2015-04-06       Impact factor: 5.824

10.  Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.

Authors:  Hermann Eichler; Pantep Angchaisuksiri; Kaan Kavakli; Paul Knoebl; Jerzy Windyga; Victor Jiménez-Yuste; Philip Harder Delff; Pratima Chowdary
Journal:  Haemophilia       Date:  2018-11-08       Impact factor: 4.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.